Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
178
resultados
Última actualización
25/08/2026 [06:57:00]
Resumen de: US20260240459A1
0000 This invention relates to a low-cost portable multispectral detection method and device for early disease diagnosis. The device is based on a CMOS multispectral sensor chip and uses natural light or halogen lamps as the light source to non-invasively detect physiological parameters from the eyes, oral cavity, and/or skin of patients. The device captures reflected light data of different wavelengths using the multispectral chip and processes the data to generate image information, subsequently identifying the corresponding test areas. By processing the initial spectral information, the device provides accurate spectral data analysis to determine physiological parameters such as glucose etc., enabling early diagnosis of diseases such as diabetes, etc. It features real-time data analysis and wireless data transmission, offering a convenient solution for large-scale health monitoring and telemedicine.
Resumen de: US20260242737A1
0000 A culture medium and a culture medium additive which can promote myogenic differentiation. The culture medium and a culture medium additive contain ergothioneine, ascorbic acid 2-glucoside, ascorbic acid, or a combination thereof. A kit, pharmaceutical composition, food, and drink may also promote myogenic differentiation.
Resumen de: WO2026171056A1
Disclosed in the present application are a blood glucose assessment method, a user interface, and a related apparatus. The method involves two phases: a calibration phase and an assessment phase. In the calibration phase, physical sign data used for reflecting a physical condition of a user, and a blood glucose value can be acquired, and a personalized blood glucose assessment model applicable to the user is obtained on the basis of the physical sign data and the blood glucose value. Then, in the assessment phase, physical sign data of the user is acquired, and a blood glucose result of the user is assessed on the basis of the physical sign data and the blood glucose assessment model, wherein the blood glucose result can be used for indicating a blood glucose condition of the user. In the method, in the calibration phase, the model is determined on the basis of the physical sign data and the blood glucose value, which improves the accuracy of the model. Moreover, in the assessment phase, the blood glucose condition of the user can be assessed without acquiring the blood glucose value, so that the trouble of acquiring the blood glucose value is reduced, and the blood glucose result that is accurate and conforms to an actual condition of the user can be obtained.
Resumen de: US20260241102A1
0000 Disclosed herein are techniques related to automatic real-time meal detection. In some embodiments, the techniques involve obtaining a plurality of glucose concentration values and a plurality of plasma insulin concentration values. At least one of the plurality of glucose concentration values is obtained within a time range of a determination of a respective plasma insulin concentration value of the plurality of plasma insulin concentration values. The techniques further involve generating an output based on applying a meal detection model to the plurality of glucose concentration values and the plurality of plasma insulin concentration values and determining, based on the output, that a glucose concentration value of the plurality of glucose concentration values corresponds to an ongoing glycemic response to a meal.
Resumen de: US20260240467A1
0000 A method for compensating for a life-lengthening agent for a glucose sensor includes accessing first and second electrochemical impedance spectroscopy (EIS) values of at least one parameter based on first and second EIS procedures performed on EIS signals from a working electrode of the glucose sensor, calculating a change in the at least one parameter between the first and second EIS values, estimating a concentration of the agent based on the change in the at least one parameter, and calculating a model effect in response to the concentration. In a case where the model effect is not greater than the threshold, the method further includes adjusting a sensor glucose value based on the concentration and sensor signals from the working electrode, and displaying the adjusted sensor glucose value.
Resumen de: US20260241109A1
0000 Systems, methods, and devices relate, generally, to autonomous dose injection. One or more examples relate to a durable insulin injection device. Such a durable dose injection device may include a chamber, a drive mechanism, a logic circuit, and an actuator. The chamber may be to receive a prefilled insulin cartridge. The drive mechanism may be to apply force to a plunger of a received prefilled insulin cartridge, the plunger arranged to move within the received cartridge responsive to force applied by the drive mechanism and thereby push fluid in the received cartridge toward an interface for dispensing fluid. The logic circuit may be to receive analyte data for the user and calculate a target amount of insulin to deliver to a user. The dose-ready confirmation actuator may be for the user to actuate to cause the delivery of insulin to the user. In one or more examples, the durable insulin injection device does not provide the user with an indication of the calculated target amount of insulin for non-zero calculated target amounts of insulin.
Resumen de: US20260241096A1
0000 An infusion element for infusing a substance into a body of a person, comprising: a housing that is suitable for being attached to the skin of said person; an infusion means for infusing the substance into the body of said person, said infusion means being arranged on and/or protruding from the first surface of the housing; at least one sensor for sensing a characteristic of the person, said sensor being arranged on and/or protruding from the first surface of the housing; wherein in use of the infusion element the infusion means is arranged for infusing said substance at a first depth and said sensor is arranged for sensing the characteristic at a second, different depth. A system for regulating the concentration of glucose in the blood of a person comprising such an infusion element.
Resumen de: US20260240464A1
0000 A composition for blood glucose measurement includes a copolymer including three types of monomers having a hydrophobic group, a hydrophilic group, and a boronic acid moiety, and a conductive material mixed with the copolymer, thereby enabling volume changes in response to glucose to be converted into electrical signals. An electrochemical sensor for blood glucose measurement includes a working electrode that includes the composition.
Resumen de: US20260241095A1
0000 An infusion system comprising: a device configured to deliver medication to a user through an infusion catheter, wherein the device includes a housing configured to receive the infusion catheter and to maintain the infusion catheter in the user after insertion; and a detachable activation mechanism for deploying the device for delivering medication to the user, wherein the detachable activation mechanism comprises a trigger and a retraction mechanism that includes an introducer needle for introducing the infusion catheter into the user, wherein the detachable activation mechanism is configured to releasably connect to the housing, wherein the detachable activation mechanism is configured to insert the infusion catheter into the user, automatically release the detachable activation mechanism from the housing responsive to activation of the trigger and automatically retract the introducer needle into the needle retraction assembly to shield the needle upon the automatic release of the detachable activation mechanism.
Resumen de: US20260240457A1
Provided is a sensor applicator assembly for a blood glucose monitoring including a body-attachable unit including an upper frame and a lower frame that is disposed under the upper frame and has a surface attached to a body and an applicator within which the body-attachable unit is disposed. The upper frame includes a first area and a second area disposed under the first area and in contact with the lower frame. A perimeter of an outer peripheral surface of the second area is identical to a perimeter of an outer peripheral surface of the lower frame.
Resumen de: EP4793962A1
0001 The invention discloses a method of locating a lost device in a diabetes management system, the diabetes management system comprises at least one wearable medical device; at least one personal management device and a secondary management device, at least one of the personal management device and the secondary management device is configured to control the wearable medical device, the personal management device and the secondary management device are communicative connection with each other; when either the personal management device or the secondary management device is determined as lost, the other device is used to locate the lost one, thereby enabling the user to retrieve it with ease.
Resumen de: KR20200036122A
The present invention relates to a body attachment unit for continuous blood glucose measurement. According to the present invention, a body attachment unit is manufactured in an assembled state in an applicator to minimize extra additional work so that the body attached unit can be attached to a body only by simply operating the applicator. In particular, the body attached unit can be simply and easily used without additional work of connecting an extra transmitter by having a wireless communication chip to communicate with an external terminal. Maintenance of the body attached unit can also be more easily performed. In addition, the body attached unit can be operated by the operation of a user once the body attached unit is attached to the body of the user, and an operation start time point can be adjusted to an appropriate time point as needed. Therefore, the body attached unit can be operated in a more stabilized state to measure blood glucose more accurately.
Resumen de: US20260232232A1
A method and apparatus for analyzing a blood glucose concentration, a device, a storage medium, and a computer program product. The method comprises: acquiring intensity sets corresponding to photoplethysmography pulse wave sets for a target object in a target time period, the intensity set comprising an average alternating-current intensity and an average direct-current intensity; performing curve fitting on the intensity sets to obtain a fitting coefficient and a fitting bias; comparing the fitting bias with a bias range corresponding to the target object, and when it is determined that the fitting bias is not within the bias range, adjusting the fitting bias to obtain an adjusted fitting bias; and performing, on the basis of the adjusted fitting bias, curve fitting on the intensity sets to obtain an adjusted fitting coefficient, and taking the adjusted fitting coefficient as the blood glucose concentration of the target object in the target time period.
Resumen de: US20260231913A1
0000 Provided are: a cancer model animal in which a malignant tumor corresponding to a pathological image of human invasive cancer or metastasis has been formed or can be formed, despite the use of transplantation under the skin or into the abdominal cavity; and a method for producing the cancer model animal. One aspect of the present invention is: a cancer model animal in which tumor cells that grow in a culture medium containing L-glucose are transplanted under the skin or into the abdominal cavity; cancer model animal in which tumor cells, such as adenocarcinoma cells, that have been transplanted under the skin or into the abdominal cavity show metastasis; or a cancer model animal in which tumor cells, such as adenocarcinoma cells, that have been transplanted under the skin or into the abdominal cavity show anomaly of function of orthotopic cells.
Resumen de: US20260232901A1
A system for regulating the concentration of glucose in the blood of a person, comprising: a device for selectively supplying at least one and preferably two substances to said person; at least one and preferably two infusion sets connectable to said device; at least one sensor for measuring a glucose concentration in the blood of said person; a controller for controlling said device such that a certain amount of a said substance is supplied per time unit, wherein said controller is arranged to determine a slope of the measured glucose concentration and if said slope exceeds a first threshold value said controller is arranged to control the device to supply a pre-injection amount of said at least one substance, said pre-injection amount being a percentage of a maximum pre-injection amount, wherein said percentage is dependent on the determined slope.
Resumen de: US20260232892A1
A system for regulating the concentration of glucose in the blood of a person, comprising: a device for selectively supplying insulin and glucagon; at least two infusion sets; at least one sensor for measuring a glucose concentration in the blood of said person; and a controller for controlling said device such that a certain amount of insulin and glucagon is supplied per time unit, wherein said certain amount is chosen in accordance with the measured glucose concentration as prescribed by an insulin injection curve and a glucagon injection curve, wherein said controller is further arranged to determine if glucagon is supplied to said person in a chosen time frame, and wherein the controller is arranged to re-assess and optionally adjust the insulin injection curve based on the determination if glucagon is supplied to said person in said chosen time frame.
Resumen de: US20260232213A1
0000 A pulsewave velocity detection device provides a photodiode capable of detecting light transmission between 600-700 nm and 880-940 nm and a light emitting diode capable of transmitting the same. An optical isolation spacer separates the photodiode and the LED. A main control chip provides processing of collected pulsewave velocity signal detection by measuring with the photodetector. A microcontroller thereby calculates local metabolic rate, blood flow volume, Hb concentration, oxygen saturation, and corrected blood glucose and correlates a corrected blood glucose value to the calculated local metabolic rate, blood flow volume, Hb concentration, and oxygen saturation. The instant abstract is neither intended to define the invention disclosed in this specification nor intended to limit the scope of the invention in any way.
Resumen de: US20260232202A1
0000 A quick screening method is provided for assessing diabetic foot syndrome for a person. Both feet of the person are positioned onto a testing plate that blocks visible light and permits passage of near infrared (NIR). A multi-spectral camera device is used to simultaneously capture a thermal image and an NIR image of soles of the feet from a side of the testing plate opposite to the feet. The thermal image is aligned with and overlaid onto the NIR image, thereby obtaining an assessment image of the feet. Based on the assessment image, a determination is made regarding whether a temperature difference between a predetermined portion of one foot and a corresponding portion of the other foot exceeds 2.2° C. A potential case of diabetic foot syndrome is reported when the temperature difference exceeds 2.2° C.
Resumen de: US20260232230A1
0000 Various systems and methods are disclosed. One or more of the methods disclosed uses machine learning algorithms to predict biophysical responses from biophysical data, such as heart rate monitor data, food logs, or glucose measurements. Biophysical responses may include behavioral responses. Additional systems and methods extract nutritional information from food items by parsing strings containing names of food items.
Resumen de: US20260232736A1
Disclosed herein are methods of treating a subject having diabetes with a population of stem cell-derived islet cells and one or more immunosuppressive reagents, such as an anti-thymocyte globulin binding moiety. The subject may have received an organ transplant.
Resumen de: US20260232717A1
0000 The invention relates to a terminally heat-sterilized multi-chamber container for parenteral nutrition, comprising a first chamber containing a macronutrient formulation and a second chamber comprising a vitamin B12 formulation, wherein the vitamin B12 formulation (a) is essentially free from glucose, amino acids, vitamin B1, ascorbyl palmitate and/or vitamin C; and (b) stably comprises vitamin B12 for at least 6 months at a temperature of from 1° C. to 40° C. and/or for at least 24 months at a temperature of 25° C.
Resumen de: EP4789663A2
Embodiments of the present invention provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue. In embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion, or a suspensions of one or more ingredients. In embodiments of the present invention, amounts of the formulation and/or energy are effective to injure or damage tissue, nerves, and nerve endings in order to relieve disease symptoms.
Resumen de: US12702755B1
A system which provides closed loop insulin administration is disclosed. A closed loop insulin administration system which bases insulin administration on accurate glucose measurements may improve a patient's quality of life.
Resumen de: US20260224811A1
The ambulatory infusion pump system of claim 17, wherein the infusion pump does not include a display and includes a bolus button configured to enable programming of a predetermined amount of medicament, and wherein the at least one processor is configured to disable the bolus button when the higher priority interface or lower priority interface has been accessed.The ambulatory infusion pump system of claim 11, wherein the at least one processor is further configured to cause a message to display on the lower priority interface indicating that the lower priority interface is inaccessible due to the higher priority interface having been accessed.The ambulatory infusion pump system of claim 11, wherein the at least one processor is configured to automatically exit the lower priority interface if the lower priority interface is active when the higher priority interface is accessed.In an infusion pump system that includes a pump that may have a user interface for pump programming, one or more smartphones or other remote control devices that interface with the infusion pump, and/or an automated insulin delivery algorithm, there is a potential conflict between commands such as boluses being programmed on multiple devices and/or calculated by the AID algorithm at the same time. In order to avoid low glucose levels that could result from delivering multiple boluses from these various sources when only one bolus is needed, systems and methods disclosed herein provide a bolus permissio
Nº publicación: US20260224172A1 06/08/2026
Solicitante:
DEXCOM INC [US]
Dexcom, Inc.
Resumen de: US20260224172A1
Certain aspects of the present disclosure relate to methods and systems for predicting glycemic events in a patient induced as a result of physical activity. In certain aspects, a method includes monitoring a plurality of analytes of the patient continuously during a time period to obtain analyte data, the plurality of analytes including at least glucose and lactate. The method further includes processing the analyte data from the time period to determine an intensity level of physical activity engaged by the patient during the time period. The method further includes generating a glycemic event prediction using at least the analyte data for the plurality of analytes and the determination of physical activity intensity. The method further includes generating one or more recommendations for treatment for the patient based, at least in part, on the glycemic event prediction.
BOPI
Sede Electrónica
